EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

OUR much-loved astrologer Meg sadly died in 2023 but her column will be kept alive by her friend and protégée . Read on to ...

The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Prostate cancer tumor biology can differ significantly based on whether a patient is Black or white, according to data from a ...

Prostate cancer focal therapies include cryotherapy, irreversible electroporation ablation (IRE), & high-intensity focused ultrasound (HIFU).

As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances ...

A large Department of Veterans Affairs cohort study revealed key racial differences in genomic alterations among men with metastatic prostate cancer.

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85% ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma programScientific Advice Meetings confirmed with global regulators in majo ...

Cancer is a disease whose very name evokes despair in the mind and heart. The patient often loses inner strength, feeling as ...

The purpose of these estimates is to inform state and local cancer care organizations and providers, patient support programs and educators, advocates, and researchers so they can allocate resources ...